{
    "nct_id": "NCT00439166",
    "title": "Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid",
    "status": "COMPLETED",
    "last_update_time": "2018-03-15",
    "description_brief": "This study will determine if biomarkers found in the cerebrospinal fluid of people with Alzheimer's disease, are affected by treatment with two common antibiotics, doxycycline and rifampicin, suggesting a disease-modifying effect of those treatments.",
    "description_detailed": "Diagnostic markers in the cerebrospinal fluid (CSF) have become a rapidly growing research field. Potential disease-modifying drugs like the antibiotics rifampicin and doxycycline, highlight the need of improved diagnostic accuracy and offer the potential to examine how these treatments may actually exert their clinical effects.\n\nCerebrospinal fluid biomarkers (the 42 amino acid form of \u03b2-amyloid (A\u03b2), total tau, and phosphorylated tau) have been evaluated in scientific studies. Tau proteins are considered \"state\" markers, whereas A\u03b2(1-42) proteins can be used as \"stage\" markers. These CSF markers have high sensitivity to differentiate early AD from normal aging, depression, alcohol dementia and Parkinson's disease. When these biomarkers are used in combination with a medical history, clinical examination, laboratory tests and brain imaging, the diagnostic accuracy is improved.\n\nMatrix metalloproteinase (MMP) dysregulation is thought to contribute to a variety of pathological conditions such as arthritis, cancer, atherosclerosis, aneurysms, nephritis, tissue ulcers, and fibrosis. In addition, MMP involvement has been demonstrated in the pathogenesis of a variety of CNS disorders, including bacterial and viral disorders, stroke, multiple sclerosis, ALS, and AD.\n\nThere is an inflammatory response in AD. This includes complement activation, elevated C-reactive protein (CRP), elevated pro-inflammatory cytokines (including IL-1-\u03b2, IL-6, TNF-\u03b1, TGF-\u03b2, S100-\u03b2), chemokine alterations (IL-8, MIP-1-\u03b1, MIP-1-\u03b2, MCP-1), and microglial.\n\nWe are measuring the biochemical markers of A\u03b2(1-40) and A\u03b2(1-42), P-tau and T-tau, matrix metalloproteinases (MMP-2, MMP-9), pro-inflammatory cytokines (IL-1beta, TNF-alpha), and anti-inflammatory cytokines (IL-4 and IL-10) at the start and one year after treatment in the multi-centered, randomized, controlled, trial of disease-modifying drugs rifampicin and/or and doxycycline to slow the progress of Alzheimer's disease by affecting the production of these biomarkers.",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "doxycycline",
        "rifampicin (rifampin)"
    ],
    "placebo": [
        "placebo matched to doxycycline",
        "placebo matched to rifampin"
    ],
    "explanation_target": [
        "Reason: The trial tests whether treatment with doxycycline and rifampicin changes cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (A\u03b242, total tau, phosphorylated tau, inflammatory markers), which is an investigation of a potential disease-modifying effect rather than only symptomatic relief. The study title and description explicitly state the goal of assessing effects on AD biomarkers in CSF. \ue200cite\ue202turn1search1\ue201",
        "Act: Key extracted details \u2014 interventions are the antibiotics doxycycline and rifampicin (small\u2011molecule drugs). Doxycycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding the 30S ribosomal subunit. \ue200cite\ue202turn0search4\ue201 Rifampicin (rifampin) is a rifamycin antibiotic that inhibits bacterial DNA-dependent RNA polymerase. \ue200cite\ue202turn0search0\ue202turn0search5\ue201 The trial is randomized/controlled with drug and matched placebos and measures CSF A\u03b2, total/p-tau, MMPs, and cytokines before and after treatment to test a disease-modifying hypothesis. \ue200cite\ue202turn1search1\ue201",
        "Reflect: Classification rationale and ambiguity \u2014 both interventions are small\u2011molecule antibiotics (not biologics) being tested for an effect on AD biomarkers (a disease-modifying outcome). Therefore the best fit among the provided categories is \"disease-targeted small molecule.\" Note ambiguity: doxycycline and rifampicin are not classical, mechanism\u2011specific anti\u2011amyloid or anti\u2011tau therapeutics, but preclinical and some clinical data suggest they may affect A\u03b2/tau oligomers, clearance mechanisms (e.g., rifampicin upregulates transporters and reduces A\u03b2 oligomers in models) and inflammation, which is why they were tested as potential disease\u2011modifying small molecules. \ue200cite\ue202turn1search3\ue202turn1search7\ue201",
        "Web search results (key sources used): 1) Trial record: Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid (NCT00439166) \u2014 trial description, interventions, biomarker endpoints. \ue200cite\ue202turn1search1\ue202turn1search0\ue201 2) Doxycycline drug info \u2014 tetracycline antibiotic, mechanism: 30S ribosomal subunit inhibition. \ue200cite\ue202turn0search4\ue201 3) Rifampicin drug info \u2014 rifamycin antibiotic, mechanism: inhibition of bacterial RNA polymerase. \ue200cite\ue202turn0search0\ue202turn0search5\ue201 4) Preclinical/clinical rationale: studies reporting rifampicin (and related compounds) can reduce A\u03b2 oligomers, enhance A\u03b2 clearance (LRP1/P-gp induction), and show neuroprotective effects in models; prior clinical trials of doxycycline+rifampin have been performed in AD. \ue200cite\ue202turn1search3\ue202turn1search9\ue202turn1search6\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The trial tests two repurposed small\u2011molecule antibiotics (doxycycline, rifampicin) and measures multiple AD biomarkers in CSF (A\u03b242, total tau, phosphorylated tau, and inflammatory markers). The agents are not single-mechanism, canonical anti\u2011amyloid or anti\u2011tau biologics; preclinical/clinical rationales attribute multiple possible actions (reducing A\u03b2 oligomers, modulating proteostasis/clearance, and anti\u2011inflammatory/neuroprotective effects), so the intervention implicates more than one CADRO domain.",
        "Act: Extracted details \u2014 drugs: doxycycline (tetracycline antibiotic; canonical mechanism: binds bacterial 30S ribosomal subunit) and rifampicin/rifampin (rifamycin antibiotic; canonical mechanism: inhibits bacterial DNA\u2011dependent RNA polymerase). Trial endpoints: CSF A\u03b242, total tau, p\u2011tau, matrix metalloproteinases, cytokines (inflammation markers). No single, explicit human molecular target (e.g., a specific human enzyme or receptor) is specified in the trial record; instead the hypothesis is that these small molecules may alter amyloid/tau oligomers, clearance pathways, and inflammatory processes. Given these multiple plausible mechanisms, assign R) Multi\u2011target.",
        "Reflect: Classification check \u2014 because the trial explicitly measures biomarkers across amyloid, tau, and inflammation and the drugs have proposed effects on several pathways (amyloid oligomers/clearance, proteostasis, inflammation), the most appropriate CADRO classification is R) Multi\u2011target. If one insisted on a single-category assignment, proteostasis/proteinopathies (I) or inflammation (F) could be argued, but that would neglect the multi-modal rationale and endpoints. The trial does not describe a non\u2011therapeutic diagnostic procedure, so 'T) Other' is not appropriate."
    ]
}